MarketCap
Facebook
X
TelegramQuartalsbericht 2023-Q2
hinzugefügt 14.08.2023
Zynerba Pharmaceuticals Operativer Cashflow 2011-2026 | ZYNE
Operativer Cashflow Jährlich Zynerba Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -23 M | -33.5 M | -41.3 M | -34.8 M | -32.4 M | -25.8 M | -20.4 M | -9.79 M | -3.54 M | -118 K | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -118 K | -41.3 M | -22.5 M |
Operativer Cashflow Vierteljährlich Zynerba Pharmaceuticals
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -7.88 M | - | -17.3 M | -7.68 M | 201 K | - | -25.6 M | -15.6 M | -8.29 M | - | -34.3 M | -21.7 M | -11 M | - | -27.4 M | -16.4 M | -9.52 M | - | -26.2 M | -19.3 M | -10.4 M | - | -19.1 M | -15.3 M | -7.65 M | - | -14.9 M | -9.35 M | -4.67 M | - | -6.59 M | -3.49 M | -1.92 M | - | -2.07 M | -650 K | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 201 K | -34.3 M | -12.7 M |
Operativer Cashflow anderer Aktien in der Arzneimittelhersteller
| Name | Operativer Cashflow | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Aerie Pharmaceuticals
AERI
|
-99.2 M | - | - | $ 754 M |  USA |
 |
Alimera Sciences
ALIM
|
-14.3 M | - | - | $ 142 M | USA |
 |
Canopy Growth Corporation
CGC
|
-166 M | $ 1.08 | - | $ 116 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
-12.7 M | - | 7.5 % | $ 6.35 M | USA |
 |
Evolus
EOLS
|
-42.3 M | $ 5.59 | - | $ 360 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-25.9 M | - | 0.86 % | $ 117 M | USA |
 |
Agile Therapeutics
AGRX
|
-9.58 M | - | 10.11 % | $ 58.2 M | USA |
 |
Harrow Health
HROW
|
43.9 M | $ 39.22 | - | $ 1.44 B | USA |
 |
Catalent
CTLT
|
268 M | - | - | $ 11.5 B | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-46.9 M | - | - | $ 2.06 B |  France |
 |
China Pharma Holdings
CPHI
|
-466 K | $ 0.58 | 5.64 % | $ 10.1 M |  China |
 |
DURECT Corporation
DRRX
|
-34.4 M | - | - | $ 50.1 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-612 K | $ 3.67 | - | $ 51.6 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
50.7 M | - | -39.89 % | $ 27.7 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-462 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Endo International plc
ENDP
|
435 M | - | - | $ 28.9 M |  Irlanda |
 |
HEXO Corp.
HEXO
|
-43.1 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Evoke Pharma
EVOK
|
-4.98 M | - | - | $ 36.6 M | USA |
 |
Organogenesis Holdings
ORGO
|
14.2 M | $ 2.87 | - | $ 378 M | USA |
 |
Aurora Cannabis
ACB
|
-211 M | $ 3.65 | - | $ 86.3 M | Canada |
 |
Perrigo Company plc
PRGO
|
238 M | $ 11.69 | -0.04 % | $ 1.62 B | USA |
 |
Athenex
ATNX
|
-131 M | - | -23.39 % | $ 1.76 M | USA |
 |
Jupiter Wellness
JUPW
|
-7.57 M | - | - | $ 33.6 M | USA |
 |
Emergent BioSolutions
EBS
|
-206 M | $ 8.77 | -0.11 % | $ 449 M | USA |
 |
Assertio Holdings
ASRT
|
49.6 M | $ 12.07 | - | $ 857 M | USA |
 |
Sundial Growers
SNDL
|
-155 M | $ 1.54 | - | $ 3.37 M | Canada |
 |
Bausch Health Companies
BHC
|
1.03 B | $ 5.63 | 0.09 % | $ 2.05 B | Canada |
 |
Lannett Company
LCI
|
-7.12 M | - | 1.15 % | $ 7.11 M | USA |
 |
TherapeuticsMD
TXMD
|
-159 M | $ 2.16 | - | $ 22.6 M | USA |
 |
Veru
VERU
|
-21.7 M | $ 2.51 | - | $ 339 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-51.4 M | - | - | $ 193 M | Canada |
 |
Viatris
VTRS
|
2.9 B | $ 14.71 | - | $ 17.7 B | USA |
 |
OrganiGram Holdings
OGI
|
-28.6 M | $ 1.39 | - | $ 402 M | Canada |
 |
cbdMD
YCBD
|
-353 K | $ 0.77 | -1.43 % | $ 3.32 M | USA |
 |
ProPhase Labs
PRPH
|
28.6 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-22.4 M | - | - | $ 1.42 B | USA |
 |
Rockwell Medical
RMTI
|
-9.41 M | $ 0.89 | - | $ 20.8 M | USA |
 |
Pacira BioSciences
PCRX
|
189 M | $ 22.86 | - | $ 1.06 B | USA |
 |
PetIQ
PETQ
|
61.9 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
-20.5 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
-32.1 M | - | -27.8 % | $ 2.56 M | USA |
 |
Recro Pharma
REPH
|
-1 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
-51.7 M | $ 4.77 | - | $ 144 M | USA |
 |
SCYNEXIS
SCYX
|
-5.28 M | $ 0.78 | - | $ 38.9 M | USA |
 |
Solid Biosciences
SLDB
|
-100 M | $ 6.14 | - | $ 251 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-88 K | $ 2.8 | 1.82 % | $ 3.47 M | USA |
 |
Tricida
TCDA
|
-140 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
7.91 M | $ 7.3 | - | $ 4.51 B | Canada |